All In MedTech

FDA Clearance Tracker · P040047-S052

Coaptite

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 26, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 26, 2019

Approved

Time to decision

170 days

Received Jan 7, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P040047-S052
Device name
Coaptite
Applicant location
Franksville, WI
Received
Jan 7, 2019
Decided
Jun 26, 2019
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P040047

Device type

Device class
Class III

Every decision under product code LNM

FDA's approval statement

As written in FDA's record.

Approval for a Post-Approval Study Labeling update.

Source documents

Other decisions for Merz North America, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

6 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.